The legal framework around compounding restricts the activity to very narrow uses when a commercial medical product is not suitable
Surgical interventions if necessary: Surgery may be needed for structural abnormalities or persistent blockages
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a novel and effective solution, having initially been approved and marketed for glycemic control in type 2 diabetes
At 1 year, 90% of all treated patients remained off long-term prophylaxis, with 8 patients who were treated with 50 mg attack-free
Full price by dose from 0.25mg to 2.4mg, PBS listing status, first-year total cost, and free dose tracking
Rather than pursuing unproven dual therapy, use genetic and biomarker insights to evaluate which single-agent GLP-1 or dual GLP-1/GIP peptide offers the best match for your biology